Stock Research for PRTA


Featured Broker: Ally Invest

Get the due diligence for another stock.


PRTA Stock Chart & Research Data

The PRTA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PRTA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


PRTA Due diligence Resources & Stock Charts

The PRTA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PRTA Detailed Price Forecast - CNN Money CNN View PRTA Detailed Summary - Google Finance
Yahoo View PRTA Detailed Summary - Yahoo! Finance Zacks View PRTA Stock Research & Analysis -

Stock Analysis

TradeIdeas View PRTA Trends & Analysis - Trade-Ideas Barrons View PRTA Major Holders - Barrons
NASDAQ View PRTA Call Transcripts - NASDAQ Seeking View PRTA Breaking News & Analysis - Seeking Alpha
Spotlight View PRTA Annual Report - OTC Report View PRTA OTC Short Report -
TradeKing View PRTA Fundamentals - TradeKing Charts View PRTA SEC Filings - Bar Chart
WSJ View Historical Prices for PRTA - The WSJ Morningstar View Performance/Total Return for PRTA - Morningstar
MarketWatch View the Analyst Estimates for PRTA - MarketWatch CNBC View the Earnings History for PRTA - CNBC
StockMarketWatch View the PRTA Earnings - StockMarketWatch MacroAxis View PRTA Buy or Sell Recommendations - MacroAxis
Bullish View the PRTA Bullish Patterns - American Bulls Short Pains View PRTA Short Pain Metrics -

Social Media Mentions

StockTwits View PRTA Stock Mentions - StockTwits PennyStocks View PRTA Stock Mentions - PennyStockTweets
Twitter View PRTA Stock Mentions - Twitter Invest Hub View PRTA Investment Forum News - Investor Hub
Yahoo View PRTA Stock Mentions - Yahoo! Message Board Seeking Alpha View PRTA Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for PRTA - Insider Cow View Insider Transactions for PRTA - Insider Cow
CNBC View PRTA Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PRTA - OTC Markets
Yahoo View Insider Transactions for PRTA - Yahoo! Finance NASDAQ View Institutional Holdings for PRTA - NASDAQ

Stock Charts

FinViz View PRTA Stock Insight & Charts - StockCharts View PRTA Investment Charts -
BarChart View PRTA Stock Overview & Charts - BarChart Trading View View PRTA User Generated Charts - Trading View

Latest Financial News for PRTA

Prothena's (PRTA) Q4 Earnings Beat, Revenues Miss Estimates
Posted on Friday February 15, 2019

Prothena's (PRTA) Q4 loss was narrower than expected, while revenues missed expectations.

Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
Posted on Thursday February 14, 2019

Prothena (PRTA) delivered earnings and revenue surprises of 41.67% and -30.71%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Prothena: 4Q Earnings Snapshot
Posted on Thursday February 14, 2019

The Dun Laoghaire, Ireland-based company said it had a loss of 56 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

Prothena Reports Fourth Quarter and Full Year 2018 Financial Results, and Provides Financial Guidance and R&D Update
Posted on Thursday February 14, 2019

Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, today reported financial results for the fourth quarter and full year 2018. “In 2018, we continued to advance our neuroscience pipeline of novel investigational therapeutics towards key milestones,” said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena. “We initiated a first-in-human Phase 1 study of PRX004 in patients with hereditary ATTR amyloidosis and remain on track to report preliminary data later this year.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.